摘要
Objective To evaluate the efficacy and safety of vedolizumab(VDZ)in the treatment of active ulcerative colitis(UC).Methods From November 1,2020 to October 30,2022,at the Department of Gastroenterology,the Sixth Affiliated Hospital of Sun Yat-sen University,81 UC patients who received VDZ treatment and completed a 14-week follow-up were retrospectively selected.The clinical data of patients,including age,disease duration,disease activity of UC were collected.
作者
唐健
TANG Jian(Dept Gastroenterol,6th Affil Hosp,Sun Yat-sen Univ/Guangdong Prov Key Lab,Colorect&Pelvic Floor Dis,Guangzhou 510655)
